Last 4,401 INR
Change Today +69.25 / 1.60%
Volume 21.4K
SKB On Other Exchanges
Symbol
Exchange
Natl India
As of 7:32 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline consumer hea (SKB) Snapshot

Open
4,350
Previous Close
4,332
Day High
4,445
Day Low
4,201
52 Week High
05/31/13 - 6,348
52 Week Low
04/23/13 - 3,645
Market Cap
185.1B
Average Volume 10 Days
11.5K
EPS TTM
119.60
Shares Outstanding
42.1M
EX-Date
03/19/13
P/E TM
36.8x
Dividend
--
Dividend Yield
1.02%
Current Stock Chart for GLAXOSMITHKLINE CONSUMER HEA (SKB)

Related News

No related news articles were found.

glaxosmithkline consumer hea (SKB) Related Businessweek News

No Related Businessweek News Found

glaxosmithkline consumer hea (SKB) Details

GlaxoSmithKline Consumer Healthcare Limited operates in the health food drinks industry in India. It manufactures and markets malt-based health food drinks, choco-malt drinks, nutritional supplements, and biscuits under the Horlicks, Boost, Maltova, and Viva brands. The company also offers over-the-counter medicine, including Crocin, a pain and body ache relieving drug; Crocin Pain Relief, a pain relief medicine; Crocin Cold and Flu, which provides relief from cold; and Crocin paediatric medicine for infants, toddlers, and older kids up to 12 years. In addition, it provides Eno, an antacid for acidity, gastric discomfort, and heat burn; Iodex for head, neck, back joint, and muscular pains, as well as Iodex creams and gels; and oral care products under the Sensodyne brand name. The company exports its products to Bangladesh, Sri Lanka, the Middle East, Nepal, Myanmar, Malaysia, Nigeria, Kenya, and Pakistan. GlaxoSmithKline Consumer Healthcare Limited was incorporated in 1958 and is headquartered in Gurgaon, India.

Founded in 1958

glaxosmithkline consumer hea (SKB) Top Compensated Officers

Managing Director, Executive Director and Mem...
Total Annual Compensation: 45.4M
Executive Director of Finance, Wholetime Dire...
Total Annual Compensation: 20.7M
Director of Operations, Wholetime Director an...
Total Annual Compensation: 21.1M
Compensation as of Fiscal Year 2012.

glaxosmithkline consumer hea (SKB) Key Developments

GlaxoSmithKline Consumer Healthcare Limited, Board Meeting, Mar 10, 2014

GlaxoSmithKline Consumer Healthcare Limited, Board Meeting, Mar 10, 2014. Agenda: To consider the actions arising out of Companies Act, 2013.

GlaxoSmithKline Consumer Healthcare Limited Reports Unaudited Standalone Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

GlaxoSmithKline Consumer Healthcare Limited reported unaudited standalone earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported net profit of INR 797.50 million or INR 18.96 per basic and diluted share compared to INR 696.50 million or INR 16.56 per basic and diluted share for the quarter ended December 31, 2012. Total income has increased from INR 7,696.20 million for the quarter ended December 31, 2012 to INR 9,135.50 million for the quarter ended December 31, 2013. Net sales/income from operations were INR 8,391.1 million compared to INR 7,090.7 million a year ago. Total income from operations was INR 8,690.0 million compared to INR 7,345.1 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 772.0 million compared to INR 685.0 million a year ago. Profit from ordinary activities before tax was INR 1,213.0 million compared to INR 1,036.0 million a year ago. For the year, the company reported net profit of INR 5,030.5 million or INR 119.60 per basic and diluted share compared to INR 4,367.7 million or INR 103.85 per basic and diluted share for the quarter ended December 31, 2012. Net sales/income from operations were INR 36,039.3 million compared to INR 30,793.6 million a year ago. Total income from operations was INR 37,487.6 million compared to INR 31,875.0 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 5,970.9 million compared to INR 5,373.3 million a year ago. Profit from ordinary activities before tax was INR 7,551.2 million compared to INR 6,487.0 million a year ago.

GlaxoSmithKline Consumer Healthcare Limited to Report Q3, 2014 Results on Feb 05, 2014

GlaxoSmithKline Consumer Healthcare Limited announced that they will report Q3, 2014 results on Feb 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKB:IN 4,401.20 INR +69.25

SKB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $6.18 USD -0.12
DC Brands International Inc $0.0008 USD -0.0001
Perrigo Co PLC $141.99 USD -1.33
Vivus Inc $5.36 USD +0.11
View Industry Companies
 

Industry Analysis

SKB

Industry Average

Valuation SKB Industry Range
Price/Earnings 36.9x
Price/Sales 5.2x
Price/Book 10.4x
Price/Cash Flow 33.8x
TEV/Sales 4.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE CONSUMER HEA, please visit www.gsk-ch.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.